Real-World HCM drug use under the microscope

NCT ID NCT06372457

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 331 adults with hypertrophic cardiomyopathy (HCM) to see how they are treated in everyday medical practice, especially with the drug mavacamten. Researchers will collect data on diagnosis, symptoms, treatments, and outcomes over time. The goal is to understand real-world patterns and improve care for HCM patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Mavacamten

What this could lead to

If successful, this study could reveal how well mavacamten works in real-world settings and help doctors better manage HCM.

What could go wrong

This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by factors like patient selection or incomplete data.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY (HCM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertrophic cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • IQVIA

    Durham, North Carolina, 27703, United States